Northern Trust Corp Grows Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Northern Trust Corp raised its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 3.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 222,764 shares of the company’s stock after acquiring an additional 8,411 shares during the quarter. Northern Trust Corp owned approximately 0.44% of Tyra Biosciences worth $3,096,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new position in Tyra Biosciences in the fourth quarter valued at about $31,000. US Bancorp DE purchased a new position in Tyra Biosciences in the fourth quarter valued at about $50,000. Aquatic Capital Management LLC purchased a new position in Tyra Biosciences in the fourth quarter valued at about $64,000. Wells Fargo & Company MN boosted its stake in Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock valued at $132,000 after acquiring an additional 3,236 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Tyra Biosciences by 130,587.5% in the fourth quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company’s stock valued at $145,000 after acquiring an additional 10,447 shares during the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Trading Down 3.1%

Shares of TYRA stock opened at $9.29 on Friday. Tyra Biosciences, Inc. has a 12 month low of $6.42 and a 12 month high of $29.60. The stock has a market capitalization of $493.21 million, a P/E ratio of -5.77 and a beta of 1.17. The firm’s 50 day moving average is $9.43 and its 200 day moving average is $12.62.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. On average, equities analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. Piper Sandler started coverage on shares of Tyra Biosciences in a research note on Wednesday. They set an “overweight” rating and a $33.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.